💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Yatharth Hospital & Trauma Care Services Limited is engaged in providing healthcare services, operating hospitals and other allied services. Its facilities include amenities, guidelines for admission, visitor policy, helpdesk, empanelment’s, and preventive health checkup. It…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A decent, fast-growing business, priced for perfection — but flagged on governance.
Yatharth Hospital & Trauma Care is scored on the pharma / healthcare framework. It keeps a healthy 13.8% of every rupee of sales as net profit. Those profits are backed by real cash — operating cash flow runs 1.20× reported profit. Free cash flow is worth about -4.0% of its market value.
Over the last 3 years revenue compounded at 33%/yr and profit at 37%/yr. Book value itself has compounded 115%/yr — the hallmark of a genuine compounder. Return on equity is a modest 10.2%. In the latest quarter profit grew 2% versus the prior quarter.
At 56× earnings, the stock sits at the 98th percentile of its own 3.3-year range — the expensive end of where it has historically traded. Today's price already implies ~23%/yr earnings growth sustained for a decade — a demanding bar. The forensic screen raises a red flag: Share count up 44% over 4 years — heavy equity dilution.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 54.46 | 75.62 | better |
| P/B | 5.27 | 3.49 | worse |
| EV/EBITDA | 27.07 | 19.95 | worse |
| ROE | 10.16 | — | — |
| ROCE | 10.79 | 10.81 | worse |
| ROA | 7.01 | 3.84 | better |
| Quick Ratio | 3.76 | — | — |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Apollo Hospitals | 52.0 | 11.4 | 21.1% |
| Max Healthcare | 65.9 | 8.0 | 12.2% |
| Manipal Health Enterprises | 93.9 | 5.2 | 10.6% |
Revenue has grown every year across all 4 financial years shown. 33% CAGR over 3 years — high-growth territory. Growth is accelerating — latest year outpaced the prior year's rate.
Net profit has risen every year — the hallmark of a compounder. Profit is growing faster than revenue (37% vs 33%) — margin expansion is at work. The latest year saw a +30% swing — check if it's a one-off or structural.
Operating margins have been stable around 18% — no major structural shift.
ROE at 9% — modest; the capital isn't working hard. Capital efficiency declining — ROE down 27pp.
EPS has grown every year — each share earns more than the last, consistently. Profit grew faster than EPS (37% vs 22%) — share dilution is eroding per-share value. 22% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
1 of 4 years had negative operating cash flow — profitability on paper may not translate to cash. Cash conversion at 1.2× PAT — earnings are well-backed by cash; strong accrual quality. Investing outflows exceed operating cash — the company relies on external funding to finance expansion.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 14% sequentially — momentum is building. Run-rate stepping up — recent quarters average 21% above earlier ones.
Quarterly margins are compressing (14% → 11%) — more revenue isn't translating to proportionally more profit.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.3y median.
Promoter holding at 55.8% — majority control intact.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.